Business Description
Tonix Pharmaceuticals Holding Corp
NAICS : 325412
SIC : 2834
ISIN : US8902604094
Description
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.25 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -13.56 | |||||
| Beneish M-Score | -0.32 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 60.1 | |||||
| 3-Year EPS without NRI Growth Rate | 60.4 | |||||
| 3-Year FCF Growth Rate | 62.1 | |||||
| 3-Year Book Growth Rate | -72.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 79.17 | |||||
| Future 3-5Y Total Revenue Growth Rate | 68.46 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.51 | |||||
| 9-Day RSI | 64.84 | |||||
| 14-Day RSI | 59.95 | |||||
| 6-1 Month Momentum % | -97.05 | |||||
| 12-1 Month Momentum % | -98.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.33 | |||||
| Quick Ratio | 2.78 | |||||
| Cash Ratio | 1.86 | |||||
| Days Inventory | 469.39 | |||||
| Days Sales Outstanding | 96.05 | |||||
| Days Payable | 265.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -284.6 | |||||
| Shareholder Yield % | -204.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 20.74 | |||||
| Operating Margin % | -716.72 | |||||
| Net Margin % | -1197.86 | |||||
| FCF Margin % | -612.79 | |||||
| ROE % | -150.01 | |||||
| ROA % | -113.77 | |||||
| ROIC % | -90.05 | |||||
| ROC (Joel Greenblatt) % | -103.32 | |||||
| ROCE % | -80.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.05 | |||||
| PB Ratio | 0.39 | |||||
| Price-to-Tangible-Book | 0.39 | |||||
| EV-to-EBIT | -0.19 | |||||
| EV-to-EBITDA | -0.2 | |||||
| EV-to-Revenue | 1.39 | |||||
| EV-to-Forward-Revenue | 1.65 | |||||
| EV-to-FCF | -0.23 | |||||
| Price-to-Net-Current-Asset-Value | 0.99 | |||||
| Price-to-Net-Cash | 3.77 | |||||
| Earnings Yield (Greenblatt) % | -526.32 | |||||
| FCF Yield % | -196.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TNXP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tonix Pharmaceuticals Holding Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11.291 | ||
| EPS (TTM) ($) | -101 | ||
| Beta | 2.49 | ||
| Volatility % | 97.41 | ||
| 14-Day RSI | 59.95 | ||
| 14-Day ATR ($) | 0.023998 | ||
| 20-Day SMA ($) | 0.156855 | ||
| 12-1 Month Momentum % | -98.94 | ||
| 52-Week Range ($) | 0.118 - 22.1376 | ||
| Shares Outstanding (Mil) | 186.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tonix Pharmaceuticals Holding Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tonix Pharmaceuticals Holding Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tonix Pharmaceuticals Holding Corp Frequently Asked Questions
What is Tonix Pharmaceuticals Holding Corp(TNXP)'s stock price today?
The current price of TNXP is $0.19. The 52 week high of TNXP is $22.14 and 52 week low is $0.12.
When is next earnings date of Tonix Pharmaceuticals Holding Corp(TNXP)?
The next earnings date of Tonix Pharmaceuticals Holding Corp(TNXP) is 2025-03-13 Est..
Does Tonix Pharmaceuticals Holding Corp(TNXP) pay dividends? If so, how much?
Tonix Pharmaceuticals Holding Corp(TNXP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers